From breakthroughs in personalised medicine; to the use of biological materials to reduce reliance on fossil fuels; and the creation of clean energy systems - the Australian Institute for Bioengineering and Nanotechnology (AIBN) is making an impact..
Our entrepreneurial mindset, global research reach, industry networks and world class facilities mean we can take solutions from the laboratory bench and work them into investment ready products.
AIBN by the numbers
Since 2004 the AIBN has attracted total research revenue of more than a quarter of a billion dollars
More than 100 industry partnerships, which are responsible for 40 per cent of AIBN funding
9 NCRIS facilities – highest concentration in the country
500 research staff and students
22 per cent of UQ’s patent portfolio is generated by the AIBN
72 per cent of AIBN publications include an international collaboration
a quarter of our publications are in the world’s top 10 per cent of journals
Founded in 2004, the AIBN, proudly based within The University of Queensland (UQ), has a unique outward facing operating model that fosters strong industry partnerships to enable translation and prepares the next generation of entrepreneurial scholars.
The AIBN is the leading bioengineering and nanotechnology research institute in Australia with a team of more than 500 researchers from around the globe who translate the most cutting-edge science from lab bench to the production line.
Our power lies in the diversity of our team, our members come from 30 different countries, more than 50 per cent are women and we have 160 PhD students and 120 postdoctoral researchers.
We exist to solve some of the world’s most serious problems and some of the projects our research teams are working on, hand in glove with industry, include:
- A research hub dedicated to working with big industry players to reprogram cells to get our society to net zero.
- The BASE facility, which is the country’s largest manufacturer of mRNA vaccines and therapies.
- A second-generation COVID-19 vaccine that has progressed to human trials and a vaccine for respiratory syncytial virus that has progressed to clinical trials.
- Nanotechnologies to create new ways of discovering and treating cancer and some of the world’s rarest diseases.
- The creation of new smart materials to repel bacteria.
- World-leading quantum dot technology for solar energy storage, as well as new materials to create more economical and better batteries.
Download our brochure to learn more
Working within the AIBN’s labs and leading these projects, we have some of the world’s most recognised academic experts, along with nine of the country’s most cutting-edge research infrastructure facilities.
We are home to the highest concentration of National Collaborative Research Infrastructure Strategy (NCRIS) facilities of any research institute in Australia, giving us access to the tools and equipment needed to take research from the laboratory bench to pilot and production, or clinical translation.
All of which position the AIBN perfectly to enable the future.
When it comes to precision medicine, advanced biomanufacturing and nanoengineered materials, if you dream it, we can do it.
